Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
Insmed (INSM) announced FDA acceptance of its New Drug Application (NDA) for brensocatib, granting Priority Review with a PDUFA target date of August 12, 2025. The drug aims to be the first-ever approved treatment for non-cystic fibrosis bronchiectasis and the first DPP1 inhibitor for neutrophil-mediated diseases.
The NDA is supported by the Phase 3 ASPEN study, which met its primary endpoint with both dosage strengths (10mg and 25mg) showing significant reduction in pulmonary exacerbations versus placebo over 52 weeks. The 25mg dose demonstrated significantly lower lung function decline. Common adverse events included COVID-19, nasopharyngitis, cough, and headache.
The company plans regulatory submissions in the EU, UK, and Japan in 2025, targeting commercial launches in 2026.
Insmed (INSM) reported strong preliminary results for 2024, with ARIKAYCE global net product sales reaching approximately $363.7 million, exceeding guidance and showing 19% year-over-year growth. The company projects 2025 ARIKAYCE revenues between $405-425 million.
Key developments include: submission of NDA for Brensocatib in bronchiectasis with anticipated U.S. launch in Q3 2025; completion of enrollment in TPIP Phase 2 study for PAH with topline data expected mid-2025; full enrollment of Phase 3 ENCORE trial for ARIKAYCE with topline data expected in Q1 2026; and FDA clearance for INS1201, their first gene therapy for DMD, with first patient dosing planned for H1 2025.
Regional ARIKAYCE sales growth: U.S. (+14%) at $254.8M, Japan (+33%) at $87.7M, and Europe (+39%) at $21.2M.
Insmed Incorporated (INSM) has announced the granting of inducement awards to 19 new employees. The awards, approved by Insmed's Compensation Committee under NASDAQ Listing Rule 5635(c)(4), were made as material inducement for employment.
The employees received options on January 2, 2025, to purchase a total of 65,930 shares of Insmed common stock at an exercise price of $69.95 per share, matching the closing price on the Nasdaq Global Select Market on the grant date.
The options come with a 10-year term and a four-year vesting schedule, with 25% vesting after the first year and 12.5% vesting every six months thereafter until the fourth anniversary, contingent on continued employment.
Insmed (Nasdaq: INSM) has announced its management team will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Monday, January 13, 2025, at 3:00 p.m. PT/6:00 p.m. ET.
The event will be accessible via webcast through the investor relations section of Insmed's website at www.insmed.com. The webcast recording will remain available for 30 days after the live presentation concludes.
Insmed (INSM) has granted inducement awards to 30 new employees as part of their employment agreements. The awards consist of options to purchase a total of 64,240 shares of Insmed common stock at an exercise price of $72.42 per share, which was the closing price on the Nasdaq Global Select Market on the grant date of December 2, 2024.
The stock options have a 10-year term and follow a four-year vesting schedule: 25% vests after the first year, followed by 12.5% vesting every six months until the fourth anniversary, contingent on continued employment with Insmed.
Insmed (Nasdaq: INSM) has announced its participation in two major investor conferences in December 2024. The company will present at the Evercore ISI HealthCONx Conference in Coral Gables, Florida, on December 4 at 11:15 a.m. ET, and at the Nasdaq 51st Investor Conference in London on December 11 at 10:30 a.m. GT (5:30 a.m. ET). Both presentations will be available via webcast on the company's investor relations website and will remain accessible for 30 days after the events.
Insmed (Nasdaq: INSM) has granted inducement awards to 27 new employees as of November 1, 2024. The awards consist of options to purchase a total of 66,740 shares of common stock at an exercise price of $68.32 per share, which was the closing price on Nasdaq Global Select Market on the grant date. These stock options have a 10-year term and follow a four-year vesting schedule: 25% vests after one year, followed by 12.5% vesting every six months until the fourth anniversary, contingent on continued employment.
Insmed (Nasdaq: INSM) has announced its participation in four major healthcare investor conferences in November 2024. The company will present at the Guggenheim Healthcare Innovation Conference in Boston (Nov. 11), UBS Global Healthcare Conference in Rancho Palos Verdes (Nov. 12), Wolfe Research Healthcare Conference in New York (Nov. 20), and Jefferies London Healthcare Conference in London (Nov. 21). All presentations will be webcast live through Insmed's investor relations website and archived for 30 days after the events.
Insmed (INSM) reported Q3 2024 financial results with ARIKAYCE revenue of $93.4 million, showing 18% growth year-over-year. The company maintained its 2024 global ARIKAYCE revenue guidance of $340-360 million. The quarter ended with approximately $1.5 billion in cash and equivalents. Key developments include the planned NDA submission for Brensocatib in Q4 2024 with potential U.S. launch in mid-2025, and a renegotiated term loan providing an additional $150 million. The company reported a net loss of $220.5 million ($1.27 per share) compared to $158.9 million ($1.11 per share) in Q3 2023.
Insmed (Nasdaq:INSM) has secured the #1 position in Science's 2024 Top Employers Survey for the fourth consecutive year. The survey, which gathered nearly 6,500 responses primarily from North America (65%), Europe (19%), and Asia/Pacific Rim (11%), evaluates companies in biotechnology and pharmaceutical industries.
The company stood out for its innovative leadership, respect for employees, social responsibility, and employee loyalty. With over 1,200 employees worldwide, Insmed has demonstrated strength in commercial and pipeline programs while maintaining its commitment to transforming patients' lives with serious diseases. The recognition highlights Insmed's distinctive culture and continued global expansion.